CoChat

Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells

Open access
Le, Hillary H., Cinaroglu, Suleyman S., Manalo, Elise C., Ors, Aysegul, Gomes, Michelle M., Duan Sahbaz, Burcin, Bonic, Karla, Origel Marmolejo, Carlos A., Quentel, Arnaud, Plaut, Justin S., Kawashima, Taryn E., Ozdemir, E. Sila, Malhotra, Sanjay V., Ahiska, Yavuz, Sezerman, Ugur, Bayram Akcapinar, Gunseli, Saldivar, Joshua C., Timucin, Emel, Fischer, Jared M. · 2021 · EBioMedicine
Cited by 42

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Senescent cells accumulate in tissues over time as part of the natural ageing process and the removal of senescent cells has shown promise for alleviating many different age-related diseases in mice. Cancer is an age-associated disease and there are numerous mechanisms driving cellular senescence in cancer that can be detrimental to recovery. Thus, it would be beneficial to develop a senolytic that acts not only on ageing cells but also senescent cancer cells to prevent cancer recurrence or progression. METHODS: We used molecular modelling to develop a series of rationally designed peptides to mimic and target FOXO4 disrupting the FOXO4-TP53 interaction and releasing TP53 to induce apoptosis. We then tested these peptides as senolytic agents for the elimination of senescent cells both in cell culture and in vivo. FINDINGS: Here we show that these peptides can act as senolytics for eliminating senescent human cancer cells both in cell culture and in orthotopic mouse models. We then further characterized one peptide, ES2, showing that it disrupts FOXO4-TP53 foci, activates TP53 mediated apoptosis and preferentially binds FOXO4 compared to TP53. Next, we show that intratumoural delivery of ES2 plus a BRAF inhibitor results in a significant increase in apoptosis and a survival advantage in mouse models of melanoma. Finally, we show that repeated systemic delivery of ES2 to older mice results in reduced senescent cell numbers in the liver with minimal toxicity. INTERPRETATION: Taken together, our results reveal that peptides can be generated to specifically target and eliminate FOXO4+ senescent cancer cells, which has implications for eradicating residual disease and as a combination therapy for frontline treatment of cancer. FUNDING: This work was supported by the Cancer Early Detection Advanced Research Center at Oregon Health & Science University.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2021.103646

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 42

Metadata

Authors
Le, H. H., Cinaroglu, S. S., Manalo, E. C., Ors, A., Gomes, M. M., Duan Sahbaz, B., Bonic, K., Origel Marmolejo, C. A., Quentel, A., Plaut, J. S., Kawashima, T. E., Ozdemir, E. S., Malhotra, S. V., Ahiska, Y., Sezerman, U., Bayram Akcapinar, G., Saldivar, J. C., Timucin, E., & Fischer, J. M.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2021-11
Volume
73
Pages
103646
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3206567829
Cited by
42
References
21
FWCI
3.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. https://app.cochat.ai/papers/10.1016/j.ebiom.2021.103646
The paper
Le, H. H., Cinaroglu, S. S., Manalo, E. C., Ors, A., Gomes, M. M., Duan Sahbaz, B., Bonic, K., Origel Marmolejo, C. A., Quentel, A., Plaut, J. S., Kawashima, T. E., Ozdemir, E. S., Malhotra, S. V., Ahiska, Y., Sezerman, U., Bayram Akcapinar, G., Saldivar, J. C., Timucin, E., & Fischer, J. M. (2021). Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.